Marc Boroditsky

Nebius CRO Marc Boroditsky sold 10,776 shares at $276.20 on 2026-06-02 for $2,976,333.36, reducing holdings by 28.6%.

Marc Boroditsky (Chief Revenue Officer) executed a substantial share reduction on 2026-06-02, selling 10,776 shares at $276.20 and lowering his post-transaction holdings to 26,886 shares from 37,662 shares. This represents a -28.6% reduction in his position at NBIS. This sale follows two prior sales at the same ticker (2026-05-15 and 2026-04-15), establishing a pattern of consistent monthly dispositions over the past two months, though outcome measurement for those prior trades is not yet available (30d n/a, 90d n/a). Across his full open-market history, Boroditsky has completed 2 prior sells at all tickers, making this transaction part of his broader disposition activity.

Chief Revenue Officer sold 4,500 shares at $217.55; part of pre-arranged 10b5-1 plan, stock down -15.7% from 52-week high.

Marc Boroditsky, Chief Revenue Officer, executed a sale of 4,500 shares at $217.55 on 2026-05-15 for $978,975.00 as part of a pre-arranged 10b5-1 trading plan adopted on 2025-09-15, reducing his holdings from 42,162 shares to 37,662 shares. This is a scheduled transaction, not a discretionary choice, meaning timing relative to current market conditions is not a meaningful signal of insider sentiment. The stock currently trades at $197.08, down -15.7% from the 52-week high of $233.73, though up 30-day (+25.4%) and 90-day (+93.6%) in the near term. His prior sell at this ticker on 2026-04-15 was followed by gains, though with a pre-arranged trading plan in effect, such historical outcomes do not indicate conviction about valuation or forward outlook. For a company with a $49.9B market cap, the modest 10.7% reduction in this executive's position carries routine significance.

CRO Marc Boroditsky sold 4,500 NBIS shares at $160.10 on Apr 15; stock up 42.1% in 30 days, 52.1% in 90 days.

Marc Boroditsky, Chief Revenue Officer of Nebius Group, sold 4,500 shares at $160.10, reducing his position by -9.6% to 42,162 shares post-transaction. The sale occurred during a period of significant stock appreciation: the stock has risen 42.1% over the past 30 days and 52.1% over the past 90 days, and currently trades at $165.34—only 0.9% below its 52-week high of $166.77. The timing of this sale during a strong uptrend warrants investor attention, as it represents a material reduction in the CRO's holdings during a period when the stock has reached near-peak valuations. This transaction provides observable context about insider positioning relative to recent price momentum and proximity to the 52-week high.